Thursday, April 11, 2013
A Japanese team has provided new
structural insights into the function of a conserved class of drug transporters
and has identified cyclic peptide inhibitors of one such protein.1
The researchers are now collaborating with PeptiDream Inc.
to develop compounds with improved drug-like properties that hit medically relevant
C. SciBX 6(14);
doi:10.1038/scibx.2013.329 Published online April 11, 2013
Y. et al. Nature; published online March 27, 2013;
doi:10.1038/nature12014 Contact: Osamu Nureki, The University of Tokyo, Tokyo,
Japan e-mail: email@example.com
Contact: Hiroaki Suga, same affiliation as above e-mail: firstname.lastname@example.org
X. et al. Nature 467, 991-994 (2010)
Y. et al. Chem. Biol. 18, 1562-1570 (2011)
J. SciBX 5(4); doi:10.1038/scibx.2012.87
AND INSTITUTIONS MENTIONED
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Innovative Medicines Initiative, Brussels, Belgium
PeptiDream Inc., Tokyo, Japan
RIKEN Advanced Science Institute, Saitama, Japan
University of California, San Diego, La Jolla, Calif.
University of Cambridge, Cambridge, U.K.
The University of Tokyo, Tokyo, Japan